For its fourth fiscal quarter (ending December 31), BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has reported E.P.S. of $-0.31 compared to $-0.38 a year ago. This performance was $-0.08 short of the consensus estimate of $-0.23. E.P.S. were $-1.18 for the latest four quarters through December 31 versus $-1.33 for the same period a year ago.
Recent Price Action
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock increased 1.4% on 2/26/24. The shares closed at $5.79. Moreover, this advance was accompanied by above average trading volume at 124% of normal. The stock has been weak relative to the market over the last nine months but has risen 2.7% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.